Jemperli received breakthrough therapy designation by the FDA for locally advanced mismatch repair deficient/microsatellite ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

Hugely promising cancer drug dostarlimab is one step closer to being widely available, after the Food and Drug Administration ...

In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...

A combination of presurgical Zejula and Jemperli showed promising treatment responses in certain patients with ER-positive, ...

This week's health news featured pivotal developments in pharmaceutical trials. GSK's cancer drug combo showed promising ...

UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula ...

GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...

GSK (GSK) announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first line advanced ovarian cancer. The trial met its primary endpoint of PFS ...

GSK plc (GSK, GSK.L) reported headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first line ...

GSK's cancer drug Jemperli cleared an important hurdle ahead of potentially expanding its European Union marketing permission, in a boost to the pharmaceutical giant's oncology pipeline.